de Wit R, Hoek F J, Bakker P J, Veenhof C H
Division of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
Ann Oncol. 1992 Apr;3(4):314-5. doi: 10.1093/oxfordjournals.annonc.a058190.
CA 15-3, MCA, and CA-549 levels were determined in the serum of 56 patients with metastatic breast cancer, all of whom had visceral and/or bone metastases. CA 15-3 was positive in the serum of 37 patients, MCA in the serum of 38 patients, and CA-549 in the serum of 39 patients. All 3 markers were positive in 36 patients, and all 3 were negative in 16 patients. In the serum of 4 patients only 1 or 2 markers were slightly elevated. Thus, the results were identical in 52 of the 56 patients. It is concluded that CA 15-3, MCA, and CA-549 are sensitive markers for advanced breast cancer, and that no advantage can be expected by combining them.
在56例转移性乳腺癌患者的血清中测定了CA 15-3、MCA和CA-549水平，所有患者均有内脏和/或骨转移。37例患者血清中CA 15-3呈阳性，38例患者血清中MCA呈阳性，39例患者血清中CA-549呈阳性。36例患者所有3种标志物均呈阳性，16例患者所有3种标志物均呈阴性。4例患者血清中仅1种或2种标志物略有升高。因此，56例患者中有52例结果相同。结论是CA 15-3、MCA和CA-549是晚期乳腺癌的敏感标志物，联合使用它们并无优势。
